Clinical trials: Influenza Prophylaxis, open to volunteers
Influenza, Community-acquired Pneumonia
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain…
- Conditions
- Influenza, Community-acquired Pneumonia, Cardiovascular Events
- Trial name
- NCT06029933
- Testing
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
- Where
- United States
- Volunteers
- 1,500,000 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).
- Trial name
- ANCHOR (NCT07159763)
- Testing
- MK-1406
- Where
- 181 sites in United States, Argentina and 3 more
- Volunteers
- 10,000 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Respiratory Infections
Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.
The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses.
- Trial name
- OmegaCold FFA (NCT07314593)
- Testing
- Omega-3 oil with 2% Free Fatty Acids, Vegatable oil
- Where
- Iceland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Landspitali University Hospital
Acute Coronary Syndrome, Heart Failure
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
The aim of this study is to evaluate the effect of offering intrahospital influenza vaccination as an adjunct to active counseling during the index hospitalization to adult patients hospitalized for acute coronary syndrome (ACS)…
- Conditions
- Acute Coronary Syndrome, Heart Failure, Influenza, Human, Cardiovascular Diseases
- Trial name
- VACC-UP (NCT07721649)
- Testing
- Intrahospital seasonal influenza vaccination offer, Standardized active influenza vaccination counseling, Standard of care discharge recommendation for ambulatory vaccination
- Where
- 2 sites in Germany
- Volunteers
- 482 people
- Sponsor
- Stephan Baldus
Pneumococcal Polysaccharide Vaccine, Influenza Vaccines
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer
Postoperative pneumonia (POP) affects 4%-24% of lung cancer surgery patients, increasing mortality, stay, costs and worsening prognosis, especially in older patients.
- Conditions
- Pneumococcal Polysaccharide Vaccine, Influenza Vaccines, Preoperative, Lung Resection Surgery
- Trial name
- NCT07885540
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine
- Volunteers
- 1,278 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy)…
- Conditions
- Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome
- Trial name
- HLA (NCT03852407)
- Testing
- Thymoglobulin, Melphalan, Fludarabine
- Where
- 10 sites in Belgium
- Volunteers
- 114 people
- Sponsor
- University of Liege
Influenza
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room…
- Trial name
- NCT07236814
- Testing
- Suraxavir marboxil, Oseltamivir
- Where
- 2 sites in China
- Volunteers
- 384 people
- Sponsor
- Capital Medical University
Influenza, COVID-19
Patient-Centered Practical Vaccine Talk For Busy Clinicians
The goal of this study is to assess the effect of an educational intervention for primary care providers (PCPs) on influenza and COVID-19 vaccine uptake among their adult patients through a pragmatic, cluster randomized trial in…
- Trial name
- PCP-VAX (NCT07651761)
- Testing
- Provider communication training
- Where
- United States
- Volunteers
- 24,500 people
- Sponsor
- University of Massachusetts, Worcester
Influenza, Human, Influenza, Human Prevention
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B
- Trial name
- NCT06800950
- Testing
- QIV, QIV Control
- Where
- 3 sites in China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Respiratory Infection Virus, COVID-19
Noseguard for Prevention of Respiratory Infections in Real-World Use
This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and…
- Conditions
- Respiratory Infection Virus, COVID-19, Influenza
- Trial name
- NCT07516977
- Testing
- Noseguard and Noseguard Night
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Influenza Prevention
Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.
This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC).
- Trial name
- NCT07730346
- Testing
- Sebaloxavir marboxil
- Where
- China
- Volunteers
- 858 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Influenza
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT06574503
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Prevention of Influenza
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
- Trial name
- NCT07133802
- Testing
- Test Group
- Volunteers
- 6,680 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza, Influenza Prophylaxis
Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting
This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical…
- Conditions
- Influenza, Influenza Prophylaxis, Nosocomial Infection
- Trial name
- NCT06762587
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- China
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Influenza Prevention, Seasonal Influenza
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Background: Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better.
- Trial name
- NCT06863142
- Testing
- VRC-FLUMOS0116-00-VP, ALFQ
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Prevention, Pandemic Influenza Prevention
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu.
- Trial name
- NCT07111078
- Testing
- VRC-FLUMOS0122-00-VP, ALFQ
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)